Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Food and Healthcare Press Releases Friday August 16, 2019 10:06
BEIJING--16 Aug--PRNewswire/InfoQuest

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent years.

Tasly has developed the proprietary 5th-generation whole-process high speed dripping pill machine, which is regarded as a landmark equipment of modern intelligent production of traditional Chinese medicine (TCM).

The machine makes it possible to transform TCM from liquid to solid in a tube of over ten meters through electromagnetic levitation vibration and cryogenic technology, and turns the former bolus into small and micro dripping pill.

The machine with independent intellectual property rights not only represents a major breakthrough in the intelligent manufacturing of modern Chinese medicine, but also represents the direction of intelligent production of modern TCM.

Tasly is also determined to promote TCM in the global market, which means its products should stand the test of international standards.

"Our responsibility is to establish advanced standard and make every detail perfect to make our products withstand the test of international standards," said Sun Wei, the QA Manager of International Industrial Center.

On the basis of deeply study towards drug regulations of China, America and Europe, Sun Wei and her team carried out research and evaluation of hundreds of testing methods and finally established 12 kinds of quality control standard methods, which fully confirm that the quality of Compound Danshen Dripping Pill is stable and controllable.

Meanwhile, Tasly is committed to R&D of urgently needed drugs in clinical practice, and constructing a greater biomedical pattern featuring the coordinated development of modern TCM, chemical drugs and biological drugs, with innovative upgrades made in every element of the whole industrial chain.

See the original link: https://en.imsilkroad.com/p/307668.html
Video - https://cdn4.prnasia.com/002071/mnr/201908/tasly/video.mp4

Latest Press Release

New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

BAVENCIO(R) (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX(R) (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for first-line...

CHMP Adopts Positive Opinion for BAVENCIO(R) (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Merck and...

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

Related Topics